↓ Cooling
Business
FDA pauses Regenxbio gene therapy trial again due to safety concerns
The FDA has placed a clinical hold on Regenxbio's gene therapy for Hunter Syndrome following safety concerns related to spine MRI findings.
Rgnx
1 trends tracked about this subject — the full history, oldest to newest below.